3-(哌啶-1-甲基)苯甲酸甲酯 | 73278-90-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-(哌啶-1-甲基)苯甲酸甲酯
• 中文别名: (2-甲基哌啶-1-甲基)苯甲酸
• 英文名称: methyl 3-(1-piperidyl methyl)benzoate
• 英文别名: Methyl 3-(piperidin-1-ylmethyl)benzoate
• CAS: 73278-90-7
• 化学式: C₁₄H₁₉NO₂
• 分子量: 233.31
• InChiKey: RJOMIJDQGNNOCO-UHFFFAOYSA-N

物化性质

• 沸点：
  331.5±25.0 °C(Predicted)
• 密度：
  1.091±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3-(哌啶-1-甲基)苯甲酸甲酯 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 正戊烷 为溶剂， 反应 2.0h， 以43.9%的产率得到3-甲基哌啶苯甲醛
  参考文献：
  名称：

  Design, synthesis and AChE inhibitory activity of indanone and aurone derivatives

  摘要：

  A new series of indanone and aurone derivatives have been synthesized and tested for in vitro AChE inhibitory activity by modified Ellman method. Most of them exhibit AChE inhibitory activities superior to rivastigmine. Further, the most potent compound 1g was selected to evaluate the effect on the acquisition and memory impairment by mice step-down passive avoidance test. (C) 2008 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2008.03.003
• 作为产物：
  描述：

  3-甲基苯甲酸甲酯 在 四氯化碳 、 溴 、 苯 作用下， 生成 3-(哌啶-1-甲基)苯甲酸甲酯
  参考文献：
  名称：

  Synthesis of Reserpine Analogs^1,2

  摘要：

  DOI：

  10.1021/jo01094a031

文献信息

• 1,2,4-Triazole-3,5-diamine derivatives
  申请人：Glaxo Group Limited

  公开号：US04318913A1

  公开（公告）日：1982-03-09

  The invention relates to compounds of the formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which R.sub.1 and R.sub.2 represent hydrogen, an aliphatic or cycloaliphatic group, or R.sub.1 and R.sub.2 together with the nitrogen atom form a 5 to 10 membered heterocyclic ring: Alk represents a straight or branched alkylene chain; Q represents furan, thiophen or benzene ring which is incorporated into the rest of the molecule; X represents --CH.sub.2 --, ##STR2## --O-- or --S-- where R.sub.6 represents hydrogen or methyl; n represents zero, 1 or 2; m represents 2, 3 or 4; R.sub.3 represents hydrogen, a substituted or unsubstituted aliphatic or aryl group and; R.sub.4 and R.sub.5, which may be the same or different, each represent hydrogen, a substituted or unsubstituted aliphatic, aryl, or together with the nitrogen atom form a heterocyclic group.

  该发明涉及式(I)的化合物及其生理上可接受的盐、水合物和生物前体，其中R.sub.1和R.sub.2代表氢、脂肪族或环脂族基团，或者R.sub.1和R.sub.2与氮原子一起形成5到10元杂环环：Alk代表直链或支链烷基链；Q代表噻吩或苯环，其嵌入到分子的其余部分中；X代表--CH.sub.2 --，--O--或--S--，其中R.sub.6代表氢或甲基；n代表零、1或2；m代表2、3或4；R.sub.3代表氢、取代或未取代的脂肪族或芳基团；R.sub.4和R.sub.5，可以相同也可以不同，每个代表氢、取代或未取代的脂肪族、芳基，或者与氮原子一起形成杂环基团。
• Scope of Aminomethylations via Suzuki−Miyaura Cross-Coupling of Organotrifluoroborates
  作者：Gary A. Molander、Paul E. Gormisky、Deidre L. Sandrock

  DOI：10.1021/jo800183q

  日期：2008.3.1

  previously reported the Suzuki−Miyaura reaction of N,N-dialkylaminomethyltrifluoroborates with aryl bromides. Herein, we report a further investigation of the scope and limitations of this palladium-catalyzed aminomethylation reaction. Aryl chlorides, iodides, and triflates coupled in good to excellent yields to give N,N-dialkylbenzylic amines. The aminomethylation of alkenyl bromides was also examined.

  我们先前报道了N，N-二烷基氨基甲基三氟硼酸酯与芳基溴化物的Suzuki-Miyaura反应。本文中，我们报告了对该钯催化的氨基甲基化反应的范围和局限性的进一步研究。芳基氯化物，碘化物和三氟甲磺酸酯以良好至优异的收率偶联，得到N，N-二烷基苄基胺。还检查了烯基溴化物的氨基甲基化。
• 1H-1,2,4-Triazole-3,5-diamine derivatives and use as selective histamine
  申请人：Glaxo Group Limited

  公开号：US04442110A1

  公开（公告）日：1984-04-10

  The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which R.sub.1 and R.sub.2, which may be the same or different, each represent hydrogen, C.sub.1-10 alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, trifluoroalkyl or alkyl substituted by hydroxy, alkoxy, amino, alkylamino, dialkylamino or cycloalkyl, or R.sub.1 and R.sub.2 may together with the nitrogen atom to which they are attached form a 5 to 10 membered alicyclic heterocyclic ring which may be saturated or may contain at least one double bond, may be unsubstituted or may be substituted by one or more C.sub.1-3 alkyl groups or a hydroxy group and/or may contain another heteroatom; Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms; Q represents a furan or thiophen ring in which incorporation into the rest of the molecule is through bonds at the 2- and 5-positions, the furan ring optionally bearing a further substituent R.sub.7 adjacent to the group R.sub.1 R.sub.2 N-Alk-, or Q represents a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4- positions; R.sub.7 represents halogen or C.sub.1-4 alkyl which may be substituted by hydroxy or C.sub.1-4 alkoxy; X represents --CH.sub.2 --, ##STR2## --O-- or --S-- where R.sub.6 represents hydrogen or methyl; n represents zero, 1 or 2; m represents 2, 3 or 4; R.sub.3 represents hydrogen, alkyl, alkenyl, aralkyl, hydroxyalkyl having at least two carbon atoms, alkoxyalkyl or aryl; and R.sub.4 and R.sub.5, which may be the same or different, each represent hydrogen, alkyl, alkyl substituted by hydroxy or C.sub.1-3 alkoxy, alkenyl, aralkyl or heteroaralkyl or R.sub.4 and R.sub.5 may together with the nitrogen atom to which they are attached form a 5 to 7-membered saturated heterocyclic ring which may contain another heteroatom, or the group ##STR3## or R.sub.4 and R.sub.5 taken together may represent the group .dbd.CR.sub.8 R.sub.9 where R.sub.8 represents aryl or heteroaryl and R.sub.9 represents hydrogen or alkyl. Preferably when X represents an oxygen atom or ##STR4## and n is zero, then Q only represents a benzene ring. The compounds of formula (I) show pharmacological activity as selective histamine H.sub.2 -antagonists.

  本发明涉及通式（I）的化合物，以及其生理上可接受的盐、水合物和生物前体，其中R.sub.1和R.sub.2，可以相同也可以不同，分别代表氢、C.sub.1-10烷基、环烷基、烯基、炔基、芳基烷基、三氟甲基或被羟基、烷氧基、氨基、烷基氨基、二烷基氨基或环烷基取代的烷基，或R.sub.1和R.sub.2可以与它们附着的氮原子一起形成一个5到10个成员的脂环杂环，该脂环杂环可以饱和或可以含有至少一个双键，可以是未取代的或可以被一个或多个C.sub.1-3烷基基团或羟基基团取代，也可以包含另一个杂原子；Alk代表1到6个碳原子的直链或支链烷基链；Q代表呋喃或噻吩环，其中结合到分子的其余部分是通过2-和5-位置的键，呋喃环可以选择地带有R.sub.1 R.sub.2 N-Alk-基团相邻的另一个取代基R.sub.7，或Q代表苯环，其中结合到分子的其余部分是通过1-和3-或1-和4-位置的键；R.sub.7代表卤素或C.sub.1-4烷基，可以被羟基或C.sub.1-4烷氧基取代；X代表--CH.sub.2 --、##STR2## --O--或--S--，其中R.sub.6代表氢或甲基；n代表零、1或2；m代表2、3或4；R.sub.3代表氢、烷基、烯基、芳基烷基、至少有两个碳原子的羟基烷基、烷氧基烷基或芳基；R.sub.4和R.sub.5，可以相同也可以不同，分别代表氢、烷基、被羟基或C.sub.1-3烷氧基取代的烷基、烯基、芳基烷基或杂芳基烷基，或R.sub.4和R.sub.5可以与它们附着的氮原子一起形成一个5到7个成员的饱和杂环，该杂环可以包含另一个杂原子，或者是基团##STR3##或R.sub.4和R.sub.5一起代表.dbd.CR.sub.8 R.sub.9基团，其中R.sub.8代表芳基或杂芳基，R.sub.9代表氢或烷基。当X代表氧原子或##STR4##且n为零时，最好Q仅代表苯环。公式（I）的化合物表现出选择性组胺H.sub.2-拮抗剂的药理活性。
• 3-[3-[1-piperidinylmethyl]phenoxy]propanamine
  申请人：Glaxo Group Limited

  公开号：US04764612A1

  公开（公告）日：1988-08-16

  The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which the variables are as defined in the specification. The compounds of formula (I) show pharmacological activity as selective histamine H.sub.2 -antagonists. Also disclosed are intermediates in the preparation of the compounds of the formula (I).

  本发明涉及通式（I）的化合物及其生理上可接受的盐、水合物和生物前体，其中变量如规范中所定义。式（I）化合物显示出作为选择性组胺H.sub.2 -拮抗剂的药理活性。本发明还揭示了制备式（I）化合物的中间体。
• Heterocyclic Compounds as CCR2 Antagonists
  申请人：Bower Justin Fairfield

  公开号：US20110136820A1

  公开（公告）日：2011-06-09

  Compounds of formula (I) Q-L-W—C(═X)—Z—P wherein Q is an amine of the formula —N(R 1 )(R 2 ); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Y 1 and Y 2 which are linked to groups L and C(X) respectively and Y 1 and Y 2 are independently selected from N and C; X is O, N, N—CN or S; Z is NR 3 ; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C—C chemokine mediated conditions.

  化合物的公式为(I)Q-L-W—C(═X)—Z—P，其中Q为公式—N(R1)(R2)的胺基；L为烷基或杂环烷基烷基连接物；W为6-或7-成员的脂肪环，包括与基团L和C(X)分别连接的环原子Y1和Y2，且Y1和Y2独立地选自N和C；X为O、N、N—CN或S；Z为NR3；P为可选取代的单环或双环芳基或杂芳基基团；以及其药学上可接受的盐或溶剂，可用于治疗C-C趋化因子介导的疾病。